Highlights Sol-Gel Technologies Ltd. Deutsche Boerse AG

Equities

4SG

IL0011417206

Delayed Deutsche Boerse AG Other stock markets 07:00:18 03/07/2024 BST			5-day change	1st Jan Change
0.81 ^EUR	+7.28%		+1.89%	-25.00%

05-28	Sol-Gel Technologies Gets Noncompliance Notice From Nasdaq	MT
05-28	Sol-Gel Technologies Ltd. Announces Resignation of Gilad Mamlok as Chief Financial Officer, Effective September 21, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sol-Gel Technologies Gets Noncompliance Notice From Nasdaq	05-28	MT
Sol-Gel Technologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-20	CI
Sol-Gel Technologies Ltd. and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize Twyneo® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel	05-16	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Sol-Gel Technologies Ltd. Screens First Patient for SGT-610 Phase 3 Study	11-30	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Sol-Gel Technologies, Searchlight Pharma Sign Licensing Deals for 2 Dermatology Drugs	06/06/23	MT
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO and EPSOLAY in Canada	06/06/23	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	10/03/23	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	10/03/23	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	21/11/22	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/08/22	CI
Sol-Gel Technologies Announces FDA Approval of EPSOLAY	25/04/22	CI
Sol-Gel Grants Galderma Holding SA the Exclusive Rights to Commercialize EPSOLAY in the United States	25/04/22	CI
Sol-Gel Technologies Announces the Commercial Availability of TWYNEO	14/04/22	CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	30/03/22	CI
Sol-Gel Technologies Says US FDA to Inspect its Epsolay Production Site in February	21/12/21	MT
Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®	21/12/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sol-Gel Technologies Ltd. Deutsche Boerse AG

Equities

4SG

IL0011417206

Highlights

Filters